Recursion CEO Chris Gibson sits on a panel at an event with Nvidia at JP Morgan 2024. A third reason Recursion and Exscientia might have seen this as the right moment for consolidation is that ...

Recursion reported $83 million in pro forma ... like DeepSeek challenge the need for scale in biopharma?" CEO Chris Gibson responded that biology's complexity necessitates scale, particularly ...

More than a decade ago, Recursion's founder and CEO Chris Gibson pioneered a machine-learning approach to selecting new drug candidates that chose REC-994 as a potential treatment for cerebral ...

Recursion chief executive Chris Gibson said that combining the two companies' technologies will create a platform that can "meaningfully improve the efficiency of drug discovery in the coming ...

Recursion Pharmaceuticals is a pioneer in AI ... and two directors are company executives: Gibson and Khan. The rest of the members of the current board are all versed in either venture capital ...

For building a pharma company that uses AI plus tiny snapshots to find treatments that humans would miss, Chris Gibson is one of Fast Company's Most Creative People in Business. These are the four ...

people and platform to further accelerate the Recursion OS as the leading full-stack TechBio platform,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “With a portfolio of 10 ...

people and platform to further accelerate the Recursion OS as the leading full-stack TechBio platform,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “With a portfolio of 10 ...

More than a decade ago, Recursion's founder and CEO Chris Gibson pioneered a machine-learning approach to selecting new drug candidates that chose REC-994 as a potential treatment for cerebral ...